Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response - Archive ouverte HAL Access content directly
Journal Articles Critical Reviews in Oncology/Hematology Year : 2016

Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response

(1, 2) , (1, 2) , (3, 4, 5) , (2, 6, 7)
1
2
3
4
5
6
7

Abstract

Non-Hodgkin lymphoma (NHL) is one of the most common malignancies and a major cause of morbidityand mortality. Radioimmunotherapy (RIT) is a novel modality for treating NHL which offers the combineduse of monoclonal antibodies for specific targeting of malignant cells and radiation for killing these cells.Despite the promising results favoring RIT in several clinical studies in different target populations andNHL types, Food and Drug Administration (FDA) approval for RIT agents is restricted to a limited numberof indications and agents, maybe because of several ambiguities that still exist in the field. One of theseambiguities are the lack of evidence-based prognostic factors that determine what patient populationwould benefit most from RIT, which is essential to know in order to optimize the efficacy and safetyof treatment with RIT. As well as selecting the best patient population for RIT, it is important to assessthe response to RIT in order to provide further treatment strategies or avoid unnecessary therapies anddiagnostic procedures. In this review we have explored the details of how to predict the efficiency of RIT∗
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01414377 , version 1 (12-12-2016)

Identifiers

Cite

Mahsa Eskian, Mirhojjat Khorasanizadeh, Francoise Kraeber-Bodere, Nima Rezaei. Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. Critical Reviews in Oncology/Hematology, 2016, 107, pp.182 - 189. ⟨10.1016/j.critrevonc.2016.10.005⟩. ⟨inserm-01414377⟩
51 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More